Compound class:
Antibody
Comment: MM-151 is a mixture of three fully human IgG1 monoclonal antibodies, each of which targets a distinct (and nonoverlapping) epitope on the extra-cellular domain of the EGFR [2]. This can be termed an oligoclonal agent. It was designed to target EGFRs with treatment-induced (acquired) resistance mutations that develop in cancer patients treated with the approved anti-EGFR monoclonals cetuximab or panitumumab. Development of the three antibody components is reported in [1].
|
References |
1. Harms BD, Kearns JD, Su SV, Kohli N, Nielsen UB, Schoeberl B. (2012)
Optimizing properties of antireceptor antibodies using kinetic computational models and experiments. Meth Enzymol, 502: 67-87. [PMID:22208982] |
2. Kearns JD, Bukhalid R, Sevecka M, Tan G, Gerami-Moayed N, Werner SL, Kohli N, Burenkova O, Sloss CM, King AM et al.. (2015)
Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic. Mol Cancer Ther, 14 (7): 1625-36. [PMID:25911688] |